Vorinostat [Zolinza; SAHA] is a novel hydroxamate structure HDAC inhibitor and was the most established HDAC inhibitor approved by the FDA for the treatment of CTCL in 2006 (18,45). Here, HDAC9 is linked to primary cutaneous T-cell non-Hodgkin lymphoma.